Original title: Walking Beyond the GRACE (Global Registry of Acute Coronary Events) Model in the Death Risk Stratification During Hospitalization in Patients With Acute Coronary Syndrome. Reference: Rapouseiras-Roubín S, et al. J Am Coll Cardiol Intv 2012;5:1117–25. Discriminatory power of risk score predictors become fundamental in the management of patients with acute coronary syndromes. This tool lets you...
What are the chances we presently have of carrying a cardiovascular disease at some point in our lives?
Original title: Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Reference: John T. Wilkins et al. JAMA. 2012; 308(17):1795-1801. This study analyzed more than 120,000 patients in the cohorts of large community studies, such as the Framingham, who did not have cardiovascular disease at the time of inclusion Considering all the age subgroups, only between 1.7%...
Jornadas Ecuador 2012
The most relevant presentations from 18° edition of SOLACI Sessions, 6th region Pacific, held on 4 and 5 October 2012 in Ecuador.
Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents
The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,...
Vascular complications after valvular replacement using catheter: PARTNER trial findings
Reference: Généreux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER...
The impact of permanent pacemaker implantation in patients undergoing percutaneous aortic valve replacement.
Reference: Buellesfeld y colaboradores (JACC in press). Percutaneous aortic valve replacement (AVR) is an innovative technique for the treatment of severe aortic stenosis (SAS); this technique has been incorporated with great enthusiasm in clinical practice, particularly for patients with excessive surgical risks. Due to the proximity of the aortic valve, AV node and His bundle, there...
Renal Denervation: a strategy that has come to stay?
Our editors talked with Dr. Marco Wainstein, an active member of SOLACI Web Editorial Board SOLACI WEB: Which is the rationale for renal denervation? Marco Wainstein, MD: The rationale for renal denervation is based on the modification of the sympathetic innervation of the renal arteries affecting both afferent and efferent nerves. Ultimately, renal denervation would...
Renal failure in acute myocardial infarction
Reference: Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as...
Hyperglycemia on admission, an excess risk for infarction
Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with...
Six Months Sufficient for Dual Antiplatelet Therapy
Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,...